WO2006105201A3 - Conjugates comprised of fatty acid and hiv gp41-derived peptide - Google Patents

Conjugates comprised of fatty acid and hiv gp41-derived peptide Download PDF

Info

Publication number
WO2006105201A3
WO2006105201A3 PCT/US2006/011474 US2006011474W WO2006105201A3 WO 2006105201 A3 WO2006105201 A3 WO 2006105201A3 US 2006011474 W US2006011474 W US 2006011474W WO 2006105201 A3 WO2006105201 A3 WO 2006105201A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
fatty acid
derived peptide
conjugates comprised
conjugate
Prior art date
Application number
PCT/US2006/011474
Other languages
French (fr)
Other versions
WO2006105201A2 (en
Inventor
Stephen Wring
Lloyd Frick
Stephen Schneider
Huyi Zhang
Jie Di
David Heilman
Original Assignee
Trimeris Inc
Stephen Wring
Lloyd Frick
Stephen Schneider
Huyi Zhang
Jie Di
David Heilman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc, Stephen Wring, Lloyd Frick, Stephen Schneider, Huyi Zhang, Jie Di, David Heilman filed Critical Trimeris Inc
Publication of WO2006105201A2 publication Critical patent/WO2006105201A2/en
Publication of WO2006105201A3 publication Critical patent/WO2006105201A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Provided is a conjugate comprised of HIV gp41 -derived peptide operatively linked to fatty acid, and pharmaceutical compositions and medicaments containing the conjugate. Also provided are methods for producing a conjugate according to the present invention which include, but are not limited to, covalently coupling a linker to the HIV gp41 -derived peptide, wherein the linker is covalently coupled to fatty acid.
PCT/US2006/011474 2005-03-30 2006-03-28 Conjugates comprised of fatty acid and hiv gp41-derived peptide WO2006105201A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US66665505P 2005-03-30 2005-03-30
US60/666,655 2005-03-30
US70615705P 2005-08-05 2005-08-05
US60/706,157 2005-08-05
US78586006P 2006-03-24 2006-03-24
US60/785,860 2006-03-24

Publications (2)

Publication Number Publication Date
WO2006105201A2 WO2006105201A2 (en) 2006-10-05
WO2006105201A3 true WO2006105201A3 (en) 2007-04-05

Family

ID=37054082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/011474 WO2006105201A2 (en) 2005-03-30 2006-03-28 Conjugates comprised of fatty acid and hiv gp41-derived peptide

Country Status (1)

Country Link
WO (1) WO2006105201A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
US20120028887A1 (en) * 2009-04-01 2012-02-02 Yeda Research And Development Co. Ltd. Lipopeptide inhibitors of hiv-1
WO2010140148A1 (en) * 2009-06-01 2010-12-09 Yeda Research And Development Co . Ltd Prodrugs containing albumin binding probe
US20130196903A1 (en) * 2010-08-11 2013-08-01 Jv Bio Srl Multimeric Inhibitors of Viral Fusion and Uses Thereof
US20170144969A1 (en) * 2014-03-13 2017-05-25 The Secretary Of State For Health Antimicrobial conjugates, method for production and uses thereof
CN105646717B (en) * 2016-01-26 2020-06-09 复旦大学 Long-acting HIV fusion inhibitor and application thereof
CN111574597B (en) * 2020-05-07 2023-03-31 中国科学院微生物研究所 anti-HIV polypeptide modified by high molecular weight PEG (polyethylene glycol), preparation method and application thereof
CN117098560A (en) * 2021-04-23 2023-11-21 中国人民解放军军事科学院军事医学研究院 Antiviral polypeptide compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CURTAIN C. ET AL.: "The interactions of the N-terminal fusogenic peptide of HIV-1 gp41 with neutral phospholipids", EUR. BIOPHYS. J., vol. 28, 1999, pages 427 - 436, XP003010201 *
GORDON ET AL.: "The amino terminal peptide of HIV-1 gp41 interacts with human serum albumin", AIDS RES. HUM. RETROVIRUSES, vol. 9, no. 11, 1993, pages 1145 - 1156, XP002114010 *

Also Published As

Publication number Publication date
WO2006105201A2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2006105201A3 (en) Conjugates comprised of fatty acid and hiv gp41-derived peptide
WO2008103693A3 (en) Chemical linkers with single amino acids and conjugates thereof
WO2008141044A3 (en) Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
WO2007038658A3 (en) Antibody-drug conjugates and methods of use
MX2008002597A (en) Process for preparing purified drug conjugates.
WO2006014673A3 (en) Insulin-oligomer conjugates, formulations and uses thereof
MX2010003588A (en) Process for the manufacture of a pharmaceutical product.
WO2002088172A3 (en) Pentapeptide compounds and uses related thereto
WO2009016516A8 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
WO2007059404A3 (en) Duocarmycin derivatives as novel cytotoxic compounds and conjugates
WO2008106186A3 (en) Activated polyoxazolines and compositions comprising the same
WO2007113224A3 (en) Conjugation process for pnag and a carrier protein
WO2006034488A3 (en) Cysteine engineered antibodies and conjugates
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
EP2810661A3 (en) Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP2368908A3 (en) Anti- angiogenic compounds
WO2007011968A3 (en) Beta-glucuronide-linker drug conjugates
WO2007062610A3 (en) Four branched dendrimer-peg for conjugation to proteins and peptides
WO2012135517A3 (en) Preparation of maytansinoid antibody conjugates by a one-step process
WO2009074678A3 (en) Anticancer conjugates of camptothecin to hyaluronic acid
WO2007105027A8 (en) Anticancer drugs conjugated to antibody via an enzyme cleavable linker
WO2008077956A3 (en) Oligonucleotide-, protein and/or peptide-polymer conjugates
IL188603A0 (en) Preparation of insulin conjugates
WO2007083190A8 (en) Water insoluble helichrysum extract, process for preparing the same and uses thereof
AU2002215904A1 (en) Compounds with a branched linker

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06739939

Country of ref document: EP

Kind code of ref document: A2